World Acceptance (WRLD) EPS Estimated At $3.81; CymaBay Therapeutics, Inc. (CBAY) Had 8 Analysts Last Week

April 22, 2018 - By Jan Rainey

Analysts expect World Acceptance Corporation (NASDAQ:WRLD) to report $3.81 EPS on May, 8.They anticipate $0.17 EPS change or 4.67% from last quarter’s $3.64 EPS. WRLD’s profit would be $34.33 million giving it 6.78 P/E if the $3.81 EPS is correct. After having $1.37 EPS previously, World Acceptance Corporation’s analysts see 178.10% EPS growth. The stock decreased 2.89% or $3.07 during the last trading session, reaching $103.26. About 42,628 shares traded. World Acceptance Corporation (NASDAQ:WRLD) has risen 109.46% since April 22, 2017 and is uptrending. It has outperformed by 97.91% the S&P500.

Among 8 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 30 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Piper Jaffray on Tuesday, July 25. Leerink Swann maintained it with “Buy” rating and $16.0 target in Tuesday, November 28 report. Roth Capital initiated it with “Buy” rating and $27.0 target in Thursday, January 25 report. The rating was upgraded by H.C. Wainwright to “Buy” on Monday, January 30. The rating was maintained by Roth Capital with “Buy” on Monday, April 16. On Friday, March 16 the stock rating was maintained by SunTrust with “Buy”. The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has “Overweight” rating given on Tuesday, July 21 by Piper Jaffray. Roth Capital initiated the stock with “Buy” rating in Friday, July 1 report. The rating was maintained by Piper Jaffray on Monday, September 11 with “Buy”. Piper Jaffray maintained CymaBay Therapeutics, Inc. (NASDAQ:CBAY) rating on Monday, July 17. Piper Jaffray has “Buy” rating and $6.5000 target. See CymaBay Therapeutics, Inc. (NASDAQ:CBAY) latest ratings:

16/04/2018 Broker: Roth Capital Rating: Buy New Target: $27.0000 Maintain
11/04/2018 Broker: Leerink Swann Rating: Buy New Target: $20.0000 Maintain
11/04/2018 Broker: Evercore Rating: Buy
28/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18.0000 Initiate
28/03/2018 Broker: Leerink Swann Rating: Buy New Target: $16.0000 Maintain
21/03/2018 Broker: Oppenheimer Rating: Buy Maintain
16/03/2018 Broker: SunTrust Rating: Buy New Target: $19.0 Maintain
16/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $16.0 Maintain
13/02/2018 Broker: Evercore Rating: Outperform Initiates Coverage On

The stock increased 0.90% or $0.12 during the last trading session, reaching $13.44. About 597,869 shares traded. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has risen 197.77% since April 22, 2017 and is uptrending. It has outperformed by 186.22% the S&P500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $786.26 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

World Acceptance Corporation engages in small-loan consumer finance business. The company has market cap of $930.53 million. The firm offers short-term small and medium-term larger installment loans, as well as related credit insurance and ancillary services and products to individuals. It has a 16.22 P/E ratio. It also provides automobile club memberships to its borrowers; and income tax return preparation and electronic filing services.

Among 5 analysts covering World Acceptance (NASDAQ:WRLD), 1 have Buy rating, 3 Sell and 1 Hold. Therefore 20% are positive. World Acceptance had 16 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was downgraded by Janney Capital on Tuesday, August 11 to “Buy”. The company was downgraded on Tuesday, January 10 by Jefferies. The company was maintained on Thursday, July 27 by Jefferies. The firm has “Sell” rating by Jefferies given on Wednesday, June 14. The firm has “Sell” rating by Jefferies given on Thursday, September 7. On Wednesday, January 3 the stock rating was maintained by Stephens with “Sell”. BMO Capital Markets maintained the shares of WRLD in report on Friday, October 6 with “Sell” rating. The company was maintained on Sunday, January 28 by BMO Capital Markets. The stock of World Acceptance Corporation (NASDAQ:WRLD) has “Sell” rating given on Thursday, August 3 by BMO Capital Markets. BMO Capital Markets maintained World Acceptance Corporation (NASDAQ:WRLD) rating on Thursday, June 15. BMO Capital Markets has “Sell” rating and $6200 target.

Investors sentiment increased to 0.86 in Q4 2017. Its up 0.02, from 0.84 in 2017Q3. It improved, as 10 investors sold World Acceptance Corporation shares while 47 reduced holdings. 16 funds opened positions while 33 raised stakes. 7.96 million shares or 0.67% less from 8.01 million shares in 2017Q3 were reported. Goldman Sachs Grp invested in 0% or 49,108 shares. Eqis accumulated 0.01% or 2,666 shares. Parametric Port Associates Ltd Llc holds 0.01% of its portfolio in World Acceptance Corporation (NASDAQ:WRLD) for 73,711 shares. California Pub Employees Retirement Sys holds 0.01% of its portfolio in World Acceptance Corporation (NASDAQ:WRLD) for 57,024 shares. Shell Asset Communications reported 13,415 shares. Great West Life Assurance Can, Manitoba – Canada-based fund reported 7,764 shares. Citigroup invested 0% in World Acceptance Corporation (NASDAQ:WRLD). Prudential Fincl reported 0.01% in World Acceptance Corporation (NASDAQ:WRLD). Dimensional Fund Advsr L P stated it has 624,478 shares or 0.02% of all its holdings. Leuthold Ltd owns 28,586 shares for 0.23% of their portfolio. Grp stated it has 4,681 shares or 0% of all its holdings. Matarin Capital Mngmt Ltd Co holds 0.04% or 6,458 shares. 7,526 are held by Arrowstreet Limited Partnership. Tiaa Cref Investment Management Ltd Liability reported 14,373 shares stake. Invesco Ltd invested 0% in World Acceptance Corporation (NASDAQ:WRLD).

By1 Jan Rainey